Is Cronos Group Inc (CRON) overvalued? · P/E 14, rev $117.6M
Cronos Group Inc (CRON) is a drug manufacturers - specialty & generic company listed on US.
This page asks whether Cronos Group Inc (CRON) looks expensive on cached numbers — not a short thesis.
Latest reported CRON revenue for 2024-12-31 was $117.6M. Net income was $40.0M. Revenue was up 34.8% from 2023-12-31 to 2024-12-31. CRON currently screens at market cap $738.3M and trailing P/E 13.6.
CRON currently screens at market cap $738.3M and trailing P/E 13.6. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next CRON 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the CRON stock page for the full model, not this heading.
Not investment advice.